NEW YORK (GenomeWeb News) — Illumina and the Mayo Clinic today said they plan to co-develop molecular diagnostics for certain undisclosed diseases, Illumina said today.
 
Under the agreement, Illumina will provide its VeraCode technology and its know-how on the BeadArray platform to Mayo Medical Laboratories, which have had the technology since January 2005.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.